Maxim Group initiated coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a research note published on Thursday morning. The firm issued a buy rating and a $135.00 price objective on the biopharmaceutical company’s stock.
“Epilepsy remains a challenging indication to treat, with over a third of patients (750k patients in the U.S.) who are inadequately controlled despite several antiepileptic drugs (market of $5B) taken concurrently. GW’s lead product, Epidiolex, an orphan drug designated oral CBD (cannabidiol), showed positive results in three P3 trials for Dravet (DS) and Lennox-Gastaut syndromes (LGS).”,” Maxim Group’s analyst wrote.
Other equities research analysts have also issued research reports about the company. Cowen and Company set a $135.00 price target on GW Pharmaceuticals PLC- and gave the stock a buy rating in a research note on Monday, February 6th. Cantor Fitzgerald set a $208.00 price target on GW Pharmaceuticals PLC- and gave the stock a buy